Skip to main content
Jennifer Crombie, MD, Oncology, Boston, MA

JenniferLeighCrombieMD

Oncology Boston, MA

Hematologic Oncology

Physician

Dr. Crombie is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Crombie's full profile

Already have an account?

  • Office

    450 Brookline Ave
    Boston, MA 02115
    Phone+1 617-632-3000

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2018
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2012 - 2015
  • University of Massachusetts Medical School
    University of Massachusetts Medical SchoolClass of 2012

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2014 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Current Considerations in AYA Hodgkin Lymphoma  
    Jennifer L Crombie, Ann S LaCasce, British Journal of Haematology

Abstracts/Posters

  • Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
    Jennifer L. Crombie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
    Jennifer L. Crombie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Study Sounds Note of Caution on Effectiveness of Covid Vaccines for Patients with Lymphoid Malignancies
    Study Sounds Note of Caution on Effectiveness of Covid Vaccines for Patients with Lymphoid MalignanciesAugust 24th, 2021
  • Matthew S. Davids, MD, MMSc, Discusses Study of Duvalisib in Combination with Venetoclax
    Matthew S. Davids, MD, MMSc, Discusses Study of Duvalisib in Combination with VenetoclaxDecember 10th, 2019